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Abstract
Objective: Inflammation may influence gestational hyperglycemia, but to date, the data from observational
studies is largely limited to results from the third trimester of pregnancy. Our objective was to evaluate first
trimester adipocytokine levels. We sought to determine whether first trimester adiponectin and tumor necrosis
factor-alpha (TNF)-alpha concentrations were independently associated and predictive of maternal glucose
tolerance, as measured by the 1-hour glucose challenge test (GCT), after adjustment for maternal lifestyle
behaviors and body mass index (BMI).
Material and Methods: Prospective study of pregnant women (n = 211) enrolled in the Parity, Inflammation, and
Diabetes Study. Nonfasting serum levels of adiponectin and TNF-r2 were measured at 8–14 weeks of pregnancy.
GCT results were abstracted from electronic prenatal records. Multiple linear regression models were developed
to determine the association of adiponectin and TNF-r2 levels with response to the GCT, adjusting for demo-
graphics, pregravid dietary intake and physical activity, first trimester BMI, and gestational weight gain.
Results: At baseline, higher adiponectin concentrations were inversely and statistically significantly associated
with maternal response to the GCT [regression coefficient (b) - 0.68; 95% confidence interval (CI): - 1.29,
- 0.06). Adjustment for lifestyle factors did not alter the association of adiponectin with the GCT (b - 0.74; 95%
CI: - 1.43, - 0.05). After adjustment for first trimester BMI, the association of adiponectin was attenuated
and no longer significant (b - 0.46; 95% CI: - 1.15, 0.24). TNF-r2 levels were not associated with the GCT
(b - 0.003; 95% CI: - 0.011, 0.005).
Conclusions: First trimester adiponectin levels are not predictive of the 1-hour GCT response, but may be a
marker for the effect of maternal BMI on glucose response to the GCT.
Introduction
It is estimated that 7%–14% of the 6 million pregnancieseach year in the United States are complicated by gesta-
tional diabetes (GDM);1 one-third of pregnancies each year
are complicated by a positive 1-hour glucose challenge test
(GCT), indicating some degree of glucose intolerance.2 Re-
sults from the Hyperglycemia and Pregnancy Outcomes
(HAPO) study3 suggest that even mild glucose intolerance
in pregnancy (i.e. hyperglycemic levels not diagnostic of
GDM) is associated with accelerated intrauterine growth,
adverse delivery outcomes,3,4 metabolic alterations in the
newborn, and maternal risk of type 2 diabetes in much
the same fashion as GDM.5 Moreover, a subset analysis of
the HAPO data showed a statistically significant relation-
ship between third trimester adipocytokine levels in the
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third trimester and glucose responses to the 2-hour 75-g oral
glucose tolerance test (OGTT).6
Inflammatory peptides, such as adiponectin and tumor
necrosis factor-alpha (TNF-a), have been linked to obesity and
type 2 diabetes in general populations.7–10 Adiponectin levels
are lower in subjects with obesity and type 2 diabetes; lower
third trimester levels are associated with gestational diabetes
and lesser degrees of maternal hyperglycemia.11–13 TNF-a
levels correlate positively with body mass index, insulin re-
sistance,14 and gestational diabetes.14,15
The objective of the current study was to determine the
feasibility of using inflammatory biomarkers in early preg-
nancy to identify women who are likely to develop third tri-
mester glucose intolerance. With the growing epidemic of
overweight/obesity and the parallel increase in glucose in-
tolerance, screening tools to identify at-risk women in early
pregnancy could improve clinical care. Using inflammatory
biomarkers for early identification of women at risk of de-
veloping gestational diabetes could change the current para-
digm of prenatal screening. To date, only one study has
prospectively assessed the association of first trimester adi-
ponectin levels with third trimester glucose tolerance;16 no
studies have assessed first trimester TNF-a levels. Also, few
studies of adipocytokines in pregnancy adjust for the influ-
ence of pregravid lifestyle behaviors (dietary intake, physical
activity) on glucose tolerance.17,18
We investigated the prospective association of first trimester
adiponectin and tumor necrosis factor-receptor 2 (TNF-r2) levels
with third trimester maternal glucose tolerance in a cohort of
healthy pregnant women, adjusting for maternal body mass
index (BMI) and pregravid factors. In light of the results of the
HAPO study, our objective was to assess the relation of first
trimester biomarker levels with varying levels of maternal gly-
cemia, as measured by response to the 1-hour GCT. Our hy-
pothesis was that first trimester adiponectin levels would be
inversely associated and predictive of maternal response to the
1-hour GCT. We also hypothesized that TNF-r2 levels would be
positively associated with response to the GCT.
Materials and Methods
The Parity, Inflammation, and Diabetes (PID) study is a
prospective study of a diverse sample of urban-based preg-
nant women. The objective of the PID study is to examine the
association of maternal prepregnancy lifestyle behaviors and
four inflammatory biomarkers (high sensitivity C-reactive
protein, interleukin-6, TNF-a, adiponectin) during pregnancy
on maternal glucose tolerance, intrauterine fetal growth, and
infant birth weight. We conducted an analysis of a subset of
data from the PID study to examine the association of first
trimester levels of adiponectin and tumor necrosis factor-re-
ceptor 2 (TNF-r2) and response to the GCT, adjusting for pre-
pregnancy dietary intake and leisure activity. This study was
approved by the Johns Hopkins institutional review board.
Participant recruitment and eligibility
The PID study is an ongoing prospective study of pregnant
women recruited in the first trimester between 2006 and 2008
at an urban-based academic medical center. Women were
eligible for recruitment if they (1) were at £ 14 weeks of ges-
tation, (2) had no self-reported or documented history of
preexisting diabetes mellitus, (3) had no history of chronic
corticosteroid use, (4) had no history of HIV or cancer, (5) had
no hypertension, (6) were able to provide written informed
consent in English, and (7) did not anticipate leaving the area
prior to delivery. Following consent, participants were offi-
cially enrolled in the study. Demographic and medical history
information was obtained. Nonfasting glucose was measured
at baseline and at 18–22 weeks’ gestation to identify and ex-
clude participants with preexisting glucose intolerance prior
to the GCT. Although the 1-hour GCT followed by a 3-hour
OGTT in those who screen positive is often used to identify
preexisting diabetes in early pregnancy by clinicians, the use
of this two-step process in the current study would have been
logistically challenging since women are recruited and en-
rolled in the study at the first prenatal visit. We used a
modified version of the American Diabetes Association cri-
teria for diagnosing type 2 diabetes19 and excluded women if
the nonfasting glucose level was ‡ 200 mg/dL (11.1 mmol/L)
1–2 hours after a meal. We also examined diurnal adjusted
nonfasting insulin levels using an exclusionary threshold
value of > 150 mU/L outlined in other investigations.20
Women were also excluded if they had a spontaneous mis-
carriage, elective termination, or fetal death or had moved
away from the area. Gestational age was determined through
a review of the electronic medical record and was based on the
obstetrician’s assessment of the last menstrual period and
prenatal ultrasound. If there was a discrepancy between the
gestational age by the last menstrual period and ultrasound,
the estimated gestational age determined by ultrasound was
assigned to the participant. The power analysis is based on the
continuous outcome of the glucose response to the 1-hour
GCT regressed on the level of TNF-r2 and adiponectin as the
independent variables. Based on the standard deviation of the
glucose response to the 1-hour GCT of 26.7 and the observed
standard deviation of 507.28 for TNF-r2, we had 80% power to
detect a regression coefficient of 0.010 or greater in a linear
regression analysis of the glucose response on TNF-r2. With
the observed standard deviation of adiponectin levels of 6.40,
we had 80% power to detect a regression coefficient of 0.79 or
greater.
Exposure variables. Clinical data were abstracted from
medical records were collected at baseline (8–14 weeks) and at
the two follow-up visits in the second (18–22 weeks) and third
(28–32 weeks) trimesters. Blood samples were obtained at
baseline and at the third follow-up visit.
Serum biomarker assays. Nonfasting maternal blood
was collected in serum separator tubes, centrifuged at 2000 ·
for 15 minutes, pipetted into 3-cc polyethylene storage con-
tainers, and stored at - 80C. Samples were batch-transported
on dry ice to the institution’s core laboratory for analysis.
Aliquots of the plasma samples were thawed and assayed for
each inflammatory biomarker. Serum adiponectin levels were
determined through radioimmunoassay (Linco; intra-assay
coefficient of variation [CV] 2.11%; inter-assay CV 6.77%).
TNF-r2 levels were measured using monoclonal antibody
enzyme-linked immunosorbent assay assays. All blood sam-
ples were handled identically throughout the processes of
blood collection, storage, retrieval, and assays. Assay results
that were clearly out of range were considered outliers and
excluded—2 study participants were considered outliers and
excluded from analyses of TNF-r2.
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Dietary intake and leisure activity
Dietary intake patterns prior to pregnancy were assessed
using a modified version of the Block Rapid Food Screener21
at the baseline interview. We calculated screener scores for
dietary intake of fruit and vegetables, meat, and snacks using
the Block algorithm. These scores were used in the calculation
of daily servings of fruit and vegetables, daily total fat intake
(grams), daily saturated fat intake (grams), daily dietary
cholesterol intake (grams), and daily percent fat intake using
equations derived and previously published by Block and
colleagues.21 The Block Rapid Food Screener ranks subjects
similarly with respect to dietary intake from total fat, satu-
rated fat, dietary cholesterol, and percentage of calories from
fat with a Spearman rank-order correlation coefficient of
r > 0.60 and fruit/vegetable intake (r > 0.71) as the gold stan-
dard.21 Dietary intake variables were evaluated as continuous
variables in the analysis. Pregravid leisure-time activity was
assessed at baseline using a standardized questionnaire by
Baecke and colleagues.22 The Baecke questionnaire is com-
monly used in epidemiologic studies, is designed to measure
habitual physical activity, and has reported test-retest reli-
ability of the leisure time index of 0.74. A leisure activity index
derived at baseline ranged from 1 (low activity) to 5 (high
activity) and was modeled as a continuous variable.
Outcome variable
Maternal response to the GCT is a standard method23 for
measuring glucose tolerance during pregnancy and a well-
established predictor of important fetal4,24 and maternal
outcomes.25,26 Participants were screened for gestational di-
abetes between 24 and 28 weeks gestation as part of routine
prenatal care using the nonfasting GCT. Venous blood was
sampled 1 hour after a 50-g oral glucose load. The GCT was
administered without regard to the time elapsed since the last
meal, in accordance with the American College of Ob-
stetricians and Gynecologists and American Diabetes Asso-
ciation23 practice guidelines. Test results were abstracted from
the electronic medical record. Maternal response to the 1-hour
GCT was modeled as a continuous variable.
Assessment of covariates
Maternal age, race (white, black, other), marital status,
years of education and income were obtained via self-report
in a personal interview at the time of enrollment. Other cov-
ariates were accessed from the electronic patient record.
Marital status was categorized into two groups: single/sep-
arated/divorced and married. Years of education completed
was categorized as < 13 years, 13–16 years, and > 16 years.
Parity was obtained via medical record abstraction and cate-
gorized into three groups: no previous live births, one live
birth, and more than one live birth. Family history of diabetes
was obtained via self-report. Participants were classified as
having a family history of diabetes if they responded ‘‘yes’’ to
having a first-degree relative (mother, father, or sibling) with
diabetes. Baseline height and weight were measured at en-
rollment into the study using a calibrated stadiometer and
scale. Maternal weight was determined using the same cali-
brated scale and was recorded at each follow-up visit for se-
rum collection. We also collected data on prepregnancy
weight, which was based on self-report. Gestational weight
gain was defined as the difference in weight at enrollment
into the study and weight at the time of the 1-hour GCT.
Body mass index (BMI), defined as weight in kilograms di-
vided by height in meters squared, and modeled as a con-
tinuous variable.
Statistical analysis
We examined each biomarker for outliers and categorized
them into tertiles. Socio-demographic, clinical, and pregravid
lifestyle characteristics were then compared across tertiles
of adiponectin and TNF-r2 using analysis of variance and
p-values for trend for continuous variables and chi-square
analysis for categorical variables. Glucose response to the
1-hour GCT was examined across tertiles of TNF-r2 and adi-
ponectin. We also examined the distribution of different GCT
threshold results across tertiles of both biomarkers.
To explore the association of first trimester adiponectin and
TNF-r2 levels with maternal response to the1-hour GCT, we
developed separate multivariable models for each biomarker,
including adiponectin and TNF-r2 levels as continuous vari-
ables and adjusting for demographics and covariates. Cov-
ariates were added to the model in a stepwise fashion in order
to assess the contribution of each category of variables on the
relationship between inflammatory biomarkers and glucose
tolerance: sociodemographic variables first (age, race, parity,
family history of type 2 diabetes), pregravid dietary intake
and leisure activity scores second, then first trimester BMI,
and finally, gestational weight gain from enrollment to the
time of the GCT. Since heavier women can underreport their
weight,27 we examined the correlation between self-reported
prepregnancy BMI and first trimester BMI based on clinically
measured height and weight. The correlation between self-
reported prepregnancy BMI and BMI at the first prenatal visit
was 0.98, indicating a high correlation. For ease of interpre-
tation, we adjusted for first trimester BMI in the multivariate
analyses.
To assess potential dose–response relationships, additional
multivariate models were developed comparing the associa-
tion of the highest tertile of adiponectin and TNF-r2 to the
lowest tertile. We also developed linear regression models
stratified by first trimester BMI (normal, overweight, obese) to
determine if the strength and direction of association of each
biomarker varied across BMI categories. Finally, we devel-
oped multiple logistic regression models to assess the rela-
tionship of adiponectin to the GCT at varying threshold
levels. All analyses were conducted using Stata statistical
software (version 9.0; Stata Corporation).
Results
Of the 326 women approached for participation, 250 (77%)
women met eligibility criteria and agreed to be enrolled in the
study. A total of 37 (15%) women were subsequently excluded
due to first trimester spontaneous miscarriage (n = 34) or de-
livery prior to completion of the GCT (n = 3). Two additional
participants were excluded from the analysis due to outlying
values of TNF-r2, leaving a total sample size for TNF-a anal-
ysis of 210 participants. A subset of these data (n = 174) were
analyzed for adiponectin levels. There were no exclusions due
to elevated non-fasting glucose levels, fetal aneuploidy early
in pregnancy, or genetic anomalies noted at delivery. There
were statistically significant differences in participant
ADIPONECTIN, TNF-R2, AND THE 1-HOUR GCT 261
characteristics across tertiles of adiponectin (Table 1). Fifty-
seven percent of women in the lowest tertile of adiponectin
were African American, while 72% of participants in the
highest tertile were white. Participants in the lowest tertile of
adiponectin had a higher average first trimester BMI com-
pared with participants in the middle and highest tertiles.
Sixty-five percent of participants in the lowest tertile had a
positive history of type 2 diabetes compared to 38% of par-
ticipants in the highest tertile of adiponectin. Cholesterol
levels were inversely related to adiponectin, with an average
value of 286.1 – 66.8 in the lowest tertile to 241.9 – 70.7 in the
highest tertile.
As shown in Table 2, a larger proportion of participants in
the highest tertile of TNF-r2 were white (56%), while the racial
composition of participants in the middle tertile was similar
(41% white; 43% African American). Maternal BMI, meat
Table 1. Maternal Demographics, Body Mass Index, Lifestyle Behaviors and Response
to the 1-Hour Glucose Challenge Test Across Tertiles of Adiponectin
Tertiles of adiponectin*
Covariates Lowest tertile Middle tertile Highest tertile p-values for trend
Age, (years), mean 28.9 – 5.6 29.8 – 5.2 31.4 – 5.1 0.03
Race, n (%), white 10 (17) 32 (55) 42 (72) < 0.001
Black 33 (57) 17 (29) 8 (14)
Asian 8 (14) 5 (9) 5 (9)
Other 7 (12) 4 (7) 3 (5)
Total No. pregnancies 2.8 – 2.1 2.2 – 1.7 2.3 – 1.4 0.11
Prepregnancy BMI** 30.8 – 8.9 24.5 – 5.4 23.8 – 3.5 < 0.001
First trimester BMI 31.6 – 9.3 25.3 – 5.5 24.8 – 4.2 < 0.001
Total weight gain (kg) 6.5 – 3.5 8.1 – 3.8 9.2 – 3.3 0.0002
Positive family history DM 37 (65%) 23 (40%) 22 (38%) 0.006
Fruit and vegetable score 15.1 – 5.6 15.0 – 4.7 15.8 – 4.7 0.65
Fruit and vegetable (servings/day) 4.8 – 2.1 4.8 – 1.7 5.1 – 1.7 0.65
Meat score 24.4 – 8.0 23.0 – 9.1 21.3 – 8.2 0.13
Saturated fat (g) 27.4 – 7.0 26.2 – 8.0 24.6 – 7.2 0.13
Percent fat (%) 36.7 – 4.8 35.9 – 5.5 34.9 – 4.9 0.13
Cholesterol (g) 286.1 – 66.8 260.7 – 76.9 241.9 – 70.7 0.005
Total fat (g) 91.3 – 19.1 87.9 – 21.9 83.7 – 19.7 0.13
Leisure activity score 2.5 – 0.6 2.8 – 0.6 2.7 – 0.7 0.09
*n = 57 for each tertile.
**Based on self-reported weight.
BMI, body mass index; DM, diabetes mellitus.
Table 2. Maternal Demographics, Body Mass Index, Lifestyle Behaviors, and Response
to the 1-Hour Glucose Challenge Test Across Tertiles of Tumor Necrosis Factor-Receptor 2
Tertiles of tumor necrosis factor-r2*
Covariates Lowest tertile Middle tertile Highest tertile p-Values for trend
Age, mean 31.1 – 4.8 29.3 – 5.7 30.5 – 5.6 0.12
Race, n (%), white 30 (43) 29 (41) 39 (56) 0.10
Black 19 (27) 30 (43) 22 (31)
Asian 11 (16) 6 (9) 4 (6)
Other 10 (14) 5 (7) 5 (7)
Total No. pregnancies 2.2 – 1.6 2.6 – 2.0 2.7 – 1.8 0.27
Prepregnancy BMI** 24.0 – 4.3 27.6 – 7.1 27.0 – 8.1 0.004
First trimester BMI 24.7 – 4.9 28.7 – 7.0 28.0 – 8.5 0.002
Total weight gain (kg) 8.7 – 3.4 7.6 – 4.3 7.6 – 3.5 0.17
Positive family history DM 34 (50%) 36 (52%) 29 (41%) 0.41
Fruit and vegetable score 15.7 – 5.2 15.6 – 4.9 14.3 – 5.2 0.20
Fruit and vegetable (servings/day) 5.0 – 1.9 5.0 – 1.8 4.5 – 1.9 0.20
Meat score 22.1 – 8.0 24.3 – 8.6 20.6 – 8.6 0.04
Saturated fat (g) 25.3 – 7.0 27.3 – 7.5 24.0 – 7.6 0.04
Percent fat (%) 35.3 – 4.8 36.7 – 5.1 34.5 – 5.2 0.04
Cholesterol (g) 258.4 – 69.2 275.6 – 73.8 242.8 – 73.2 0.03
Total fat (g) 85.7 – 19.2 91.0 – 20.5 82.1 – 20.7 0.04
Leisure activity score 2.8 – 0.6 2.6 – 0.6 2.6 – 0.6 0.10
*n = 70 for each tertile.
**Based on self-reported weight.
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scores, fat and cholesterol intake, and specific dietary intake
were higher in the middle tertile of TNF-r2 compared with the
lowest and highest tertiles. In particular, average first tri-
mester BMI ranged from 24.7 – 4.9 in the lowest tertile to
28.7 – 7.0 kg/m2 and 28.0 – 8.5, respectively, in the middle and
highest tertiles of TNF-r2. Average meat scores, dietary fat,
and cholesterol intake were highest in the middle tertile of
TNF-r2 compared to the highest and lowest tertiles of TNF-r2.
There was no difference in average leisure activity scores
across tertiles of TNF-r2.
Average glucose response to the GCT from 121 – 29 mg/
dL in the lowest tertile to 108 – 25 mg/d: in the highest tertile
of adiponectin (Table 3). Average maternal response to the
GCT was similar across tertiles of TNF-r2. A larger propor-
tion of participants with glucose levels that exceeded select
threshold values were in the lowest tertiles for adiponectin
and TNF-r2.
Multivariate analysis of adiponectin and TNF-r2 levels
and the one-hour GCT
Adiponectin levels were inversely related to the glucose
response to the GCT. In unadjusted analysis, every 1.0 lg/mL
increase in first trimester adiponectin was associated with a
0.68 lower glucose level in response to the GCT (Table 4).
After adjustment for maternal demographics (age, race, and
parity), the association of adiponectin with maternal response
to the GCT remained statistically significant. Adjustment for
pregravid lifestyle factors did not alter the magnitude of as-
sociation and the relationship remained statistically signifi-
cant (b - 0.74*; [95% confidence interval: - 1.43, - 0.05]). After
adjustment for first trimester BMI, the association of adipo-
nectin was attenuated and no longer statistically significant
(- 0.46; [ - 1.15, 0.24]). In the fully adjusted model after ges-
tational weight gain up to the time of the GCT, the association
of adiponectin with response to the GCT was further attenu-
ated (- 0.42; [ - 1.12, 0.28]) and not statistically significant.
We also examined the relation of TNF-r2 with response to
the GCT. In the unadjusted model, higher TNF-r2 concen-
trations were associated with lower glucose levels in response
to the GCT (- 0.003; [ - 0.011, 0.005]). In the fully adjusted
model, the association of TNF-r2 with the GCT was small and
not statistically significant. TNF-r2 with glucose levels in re-
sponse to the GCT. In sensitivity analyses, we included pre-
pregnancy BMI rather than first trimester BMI in Model 4
(Table 4) and found no substantial difference in the direction
or magnitude of the regression coefficients for the relation of
adiponectin (- 0.49; - 0.22, 1.19) or TNF-r2 (- 0.003; - 0.005,
0.11) with response to the GCT.
There was no statistically significant dose response rela-
tionship of adiponectin or TNF-r2 with glucose response to
the GCT. In analyses stratified by first trimester BMI cate-
gories adiponectin and TNF-r2 levels were inversely related to
maternal response to the 1-hour GCT, but these relationships
were not statistically significant (data not shown).
Table 3. Response to the 1-Hour Glucose Challenge Test Across Tertiles of Adiponectin
and Tumor Necrosis Factor-Alpha




















121 – 29 110.2 – 23 108.8 – 25* 113 – 29.4 114.5 – 24.2 114.8 – 26.9**
1-hour ‡ 140 15 5 5 25 (15%) 12 11 10 33 (17%)
1-hour ‡ 135 20 5 6 31 (18%) 14 14 13 41 (21%)
1-hour ‡ 130 22 9 9 40 (23%) 18 16 16 50 (26%)
an = 57 per tertile.
bn = 71 per tertile.
*p for trend = 0.02.
**p for trend = 0.94.
GCT, glucose challenge test; SD, standard deviation.
Table 4. Multivariable Association of Adiponectin and Tumor Necrosis Factor-r2 Concentrations
at 8- to 12-Weeks Gestation with Maternal Response to the 1-Hour GCT
Regression coefficient [95% confidence interval]
Regression models Adiponectin (mg/mL) Tumor necrosis factor-r2 (pg/mL)
Model 1: unadjusted - 0.68* [ - 1.29, - 0.06] - 0.003 [ - 0.011, 0.005]
Model 2: sociodemographics (age, race, parity, fhx diabetes) - 0.72* [ - 1.41, - 0.04] - 0.002 [ - 0.010, 0.006]
Model 3: model 2 + pregravid dietary intakea and leisure activityb - 0.74* [ - 1.43, - 0.05] - 0.001 [ - 0.010, 0.007]
Model 4: model 3 + first trimester BMI - 0.46 [ - 1.15, 0.24] - 0.004 [ - 0.012, 0.004]
Model 5: model 4 + gestational weight gainc - 0.42 [ - 1.12, 0.28] - 0.005 [ - 0.013, 0.003]
*Indicates that regression coefficient is statistically significant because the 95% confidence interval does not include zero.
aDietary intake was assessed using the Block Food Frequency Questionnaire.21
bLeisure activity was assessed with the Baecke Questionnaire.22
cRepresents weight gained from enrollment to the time of the GCT.
*Indicates that regression coefficient is statistically significant be-
cause the 95% confidence interval does not include zero.
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Logistic regression analysis of adiponectin levels
and glucose thresholds
As shown in Table 5, an increase in adiponectin levels was
statistically significantly associated with a lower likelihood of
a glucose level above 140 in response to the 1-hour GCT in the
unadjusted model. After adjustment for first trimester BMI,
the relationship was no longer statistically significant. Simi-
larly, an increase in adiponectin was associated with lesser
odds of a glucose level above 135 in response to the GCT
(Table 5). However, after adjustment for first trimester BMI
and gestational weight gain, the relationship was no longer
statistically significant. There were no relation between TNF-
r2 levels and varying thresholds of the response to the GCT.
Discussion
Prior investigations12,16,28 have reported an inverse rela-
tionship of third trimester plasma concentrations of adipo-
nectin with maternal response to the 1-hour GCT and the
diagnosis of GDM. The current study extends our under-
standing of the relation of first trimester levels with lesser
degrees of maternal glycemia. Adiponectin levels between 8
and 14 weeks of pregnancy were inversely related, but not
independently associated with maternal response to the GCT.
In multivariate analysis, the regression coefficient was mod-
erately attenuated and became nonsignificant after the addi-
tion of first trimester maternal BMI to the model. These
findings suggest that adiponectin is likely a marker for the
relation of prepregnancy or first trimester BMI on third tri-
mester glucose intolerance. Early maternal BMI has been
shown to be predictive of third trimester glucose tolerance in
several observational studies. Obesity is a known predictor of
glucose intolerance and inflammation and obesity share
common mechanistic pathways that can influence glucose
tolerance. The current study helps to better elucidate the in-
fluence of maternal BMI on the association of adiponectin
with maternal glycemia.
Our findings differ from those reported in prior studies
conducted in late pregnancy (24–28 weeks gestation). Several
factors may account for this difference. First, while insulin
resistance begins in early pregnancy, the severity of insulin
resistance at the time adiponectin was measured (8–12 weeks
gestation) may not have substantially affected adiponectin
concentrations. It may be that women who develop varying
levels of maternal glycemia do not exhibit the same decrease
in adiponectin levels early in pregnancy that have been re-
ported in the third trimester among women with overt GDM.
Second, it may be that the decrease in adiponectin levels in
response to increasing insulin resistance may be cumulative,
occurring over the course of pregnancy and culminating in the
third trimester. Longitudinal studies that show the pattern of
adiponectin levels and glucose tolerance from the first
through the third trimester may further inform the relation of
adiponectin levels with glucose response to the GCT.
We also assessed the role of TNF-r2, a novel inflammatory
marker whose association with varying levels of maternal
glycemia has not been completely investigated.28,29 In contrast
to studies in late pregnancy, there was a weak, negative rela-
tionship between TNF-r2 and maternal response to the GCT. It
may be that early TNF-r2 levels are not associated with gly-
cemic levels below the threshold for GDM. Alternatively, the
effect of TNF-r2 on the inflammatory milieu may be dimin-
ished by adiponectin levels at this stage of pregnancy. Evidence
suggests that adiponectin inhibits the production of TNF-a and
its effect on the insulin signaling cascade.30,31 Longitudinal
studies that assess levels across the course of pregnancy may
provide further insight into the role of TNF-a.
The current study is particularly relevant when viewed
within the current context of the ongoing discussions about the
best strategies to diagnose gestational diabetes. The American
Diabetes Association32 published new guidelines for evaluat-
ing glucose tolerance and gestational diabetes in 2011, based on
recommendations of the International Association of Diabetes
and Pregnancy Study Group.23 These recommendations could
result in a 2- to 3-fold increase in the number of women with
GDM or glucose intolerance. The proposed change in criteria
reflects growing concerns about the effect of maternal glycemia
on the developing fetus and further emphasizes the need for
alternative diagnostic markers for early identification of wo-
men at risk for glucose intolerance.
Strengths of the PID study include the prospective study
design, diverse cohort, and recruitment and enrollment in the
first trimester. We were able to rule out early insulin resistance
in the first and second trimesters by assessment of random
glucose levels. Also, we were able to adjust for first trimester
BMI in addition to gestational weight gain up to the time of
the GCT. In contrast to prior investigations, we adjusted for
prepregnancy dietary intake and leisure activity, factors that
have been shown to affect inflammatory markers and glucose
tolerance.
Table 5. Association of First Trimester Adiponectin Levels and Varying Thresholds
of Glucose Response to the 1-Hour GCT from Multiple Logistic Regression Models
Odds ratioa (95% confidence intervals)
Logistic regression models ‡ 140 mg/dL ‡ 135mg/dL
Model 1 (unadjusted) 0.90* (0.83, 0.98) 0.90* (0.84, 0.97)
Model 2: sociodemographics (age, race, parity, fhx diabetes) 0.90* (0.82, 0.98) 0.90* (0.82, 0.97)
Model 3: model 2 + pregravid dietary intakeb and leisure activityc 0.90* (0.83, 0.99) 0.90* (0.83, 0.98)
Model 4: model 3 + first trimester BMI 0.93 (0.85, 1.01) 0.92* (0.85, 1.00)
Model 5: model 4 + gestational weight gaind 0.92 (0.84, 1.02) 0.91 (0.83, 1.00)
*Denotes a statistically significant odds ratio because the 95% confidence interval does not include 1.
aAn odds ratio less than 1 indicates less odds of a 1-hour glucose response of 140 or greater and 135 or greater.
bDietary intake was assessed using the Block Food Frequency Questionnaire.21
cLeisure activity was assessed with the Baecke Questionnaire.22
dRepresents weight gained from enrollment to the time of the GCT.
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Our study has several limitations that deserve attention.
First, the study is limited by the absence of additional adi-
posity measures (e.g., triceps skin folds, waist circumference)
that might be important factors to incorporate into the re-
gression models. Also, the study was conducted in one aca-
demic hospital among women of relative high socioeconomic
levels, which may limit the generalizability of the findings. The
lower prevalence of GDM within our cohort despite the strong
family history of type 2 diabetes may be due, in part, to the
higher socioeconomic status and access to care. Also, the
prepregnancy activity level of our cohort was higher than that
reported in other studies of pregnant women. While we were
only able to adjust for prepregnancy/first trimester lifestyle
behaviors, our analysis represents one of the first investiga-
tions of inflammatory markers to include adjustment for these
factors. Finally, the ratio of leptin, another relevant adipocy-
tokine, to adiponectin has been associated with type 2 diabetes
in nonpregnant adults. Further studies are needed to assess the
relation of the leptin/adiponectin ratio in pregnancy.33
Conclusions
The main implication of this study is that the role of early
pregnancy levels of adiponectin and TNF-a in the develop-
ment of glucose intolerance of pregnancy deserves further
attention. Additional investigations that examine the effect of
preconception lifestyle factors on early levels of these adipo-
cytokines may improve our understanding of pregravid
characteristics and the inflammatory milieu of pregnancy.
Because of the effect of varying levels of maternal glycemia on
infant birth weight, further studies that examine the combined
influence of maternal BMI and inflammation on early in utero
growth may provide additional insight.
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